Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis

L.C. Franke, A.J.H.A. Ament, M.A.F.J. van de Laar, A. Boonen, J.L. Severens

Research output: Contribution to journalArticleAcademicpeer-review

81 Citations (Scopus)
55 Downloads (Pure)

Abstract

OBJECTIVES: To assess, quantify and summarise the cost of illness of rheumatoid arthritis (RA) and ankylosing spondylitis (AS) from the societal perspective.

METHODS: Original studies reporting costs of RA or AS were searched systematically. Both cost-of-illness studies and economic evaluations of therapies were included. Studies were appraised for patient and study characteristics, type of costs and actual costs. Reported costs were aggregated by cost categories and overall mean costs were summarised by cost domain (healthcare, patient and family, and productivity costs).

RESULTS: Overall mean costs of RA (€14,906 per year) were above that of AS (€9,374 per year), while the relative distribution of costs over cost domains was approximately similar. For both diseases, productivity costs based on the human cost approach were 3 to 10 times higher than the friction costs and accounted for more than half the total costs of both diseases.

CONCLUSIONS: Productivity costs constitute the largest part of the total cost-off-illness of RA and AS reflecting the high burden of the disease on work participation. Although total and direct costs of illness in RA were higher than in AS, the average age of AS patients was 10 years lower and therefore, lifetime costs associated with AS may actually be equal or higher.
Original languageEnglish
Article numberCER3653
Pages (from-to)0118-0123
JournalClinical and experimental rheumatology
Volume27
Issue number4, Suppl. 55
Publication statusPublished - 2009

Fingerprint

Cost of Illness
Ankylosing Spondylitis
Rheumatoid Arthritis
Costs and Cost Analysis
Friction
Health Care Costs
Cost-Benefit Analysis

Keywords

  • Ankylosing spondylitis
  • Cost-of-illness
  • Costs
  • Rheumatoid arthritis

Cite this

Franke, L. C., Ament, A. J. H. A., van de Laar, M. A. F. J., Boonen, A., & Severens, J. L. (2009). Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. Clinical and experimental rheumatology, 27(4, Suppl. 55), 0118-0123. [CER3653].
Franke, L.C. ; Ament, A.J.H.A. ; van de Laar, M.A.F.J. ; Boonen, A. ; Severens, J.L. / Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. In: Clinical and experimental rheumatology. 2009 ; Vol. 27, No. 4, Suppl. 55. pp. 0118-0123.
@article{6435b789b45046f7961204b135b334a6,
title = "Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis",
abstract = "OBJECTIVES: To assess, quantify and summarise the cost of illness of rheumatoid arthritis (RA) and ankylosing spondylitis (AS) from the societal perspective.METHODS: Original studies reporting costs of RA or AS were searched systematically. Both cost-of-illness studies and economic evaluations of therapies were included. Studies were appraised for patient and study characteristics, type of costs and actual costs. Reported costs were aggregated by cost categories and overall mean costs were summarised by cost domain (healthcare, patient and family, and productivity costs).RESULTS: Overall mean costs of RA (€14,906 per year) were above that of AS (€9,374 per year), while the relative distribution of costs over cost domains was approximately similar. For both diseases, productivity costs based on the human cost approach were 3 to 10 times higher than the friction costs and accounted for more than half the total costs of both diseases.CONCLUSIONS: Productivity costs constitute the largest part of the total cost-off-illness of RA and AS reflecting the high burden of the disease on work participation. Although total and direct costs of illness in RA were higher than in AS, the average age of AS patients was 10 years lower and therefore, lifetime costs associated with AS may actually be equal or higher.",
keywords = "Ankylosing spondylitis, Cost-of-illness, Costs, Rheumatoid arthritis",
author = "L.C. Franke and A.J.H.A. Ament and {van de Laar}, M.A.F.J. and A. Boonen and J.L. Severens",
year = "2009",
language = "English",
volume = "27",
pages = "0118--0123",
journal = "Clinical and experimental rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "4, Suppl. 55",

}

Franke, LC, Ament, AJHA, van de Laar, MAFJ, Boonen, A & Severens, JL 2009, 'Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis' Clinical and experimental rheumatology, vol. 27, no. 4, Suppl. 55, CER3653, pp. 0118-0123.

Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. / Franke, L.C.; Ament, A.J.H.A.; van de Laar, M.A.F.J.; Boonen, A.; Severens, J.L.

In: Clinical and experimental rheumatology, Vol. 27, No. 4, Suppl. 55, CER3653, 2009, p. 0118-0123.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis

AU - Franke, L.C.

AU - Ament, A.J.H.A.

AU - van de Laar, M.A.F.J.

AU - Boonen, A.

AU - Severens, J.L.

PY - 2009

Y1 - 2009

N2 - OBJECTIVES: To assess, quantify and summarise the cost of illness of rheumatoid arthritis (RA) and ankylosing spondylitis (AS) from the societal perspective.METHODS: Original studies reporting costs of RA or AS were searched systematically. Both cost-of-illness studies and economic evaluations of therapies were included. Studies were appraised for patient and study characteristics, type of costs and actual costs. Reported costs were aggregated by cost categories and overall mean costs were summarised by cost domain (healthcare, patient and family, and productivity costs).RESULTS: Overall mean costs of RA (€14,906 per year) were above that of AS (€9,374 per year), while the relative distribution of costs over cost domains was approximately similar. For both diseases, productivity costs based on the human cost approach were 3 to 10 times higher than the friction costs and accounted for more than half the total costs of both diseases.CONCLUSIONS: Productivity costs constitute the largest part of the total cost-off-illness of RA and AS reflecting the high burden of the disease on work participation. Although total and direct costs of illness in RA were higher than in AS, the average age of AS patients was 10 years lower and therefore, lifetime costs associated with AS may actually be equal or higher.

AB - OBJECTIVES: To assess, quantify and summarise the cost of illness of rheumatoid arthritis (RA) and ankylosing spondylitis (AS) from the societal perspective.METHODS: Original studies reporting costs of RA or AS were searched systematically. Both cost-of-illness studies and economic evaluations of therapies were included. Studies were appraised for patient and study characteristics, type of costs and actual costs. Reported costs were aggregated by cost categories and overall mean costs were summarised by cost domain (healthcare, patient and family, and productivity costs).RESULTS: Overall mean costs of RA (€14,906 per year) were above that of AS (€9,374 per year), while the relative distribution of costs over cost domains was approximately similar. For both diseases, productivity costs based on the human cost approach were 3 to 10 times higher than the friction costs and accounted for more than half the total costs of both diseases.CONCLUSIONS: Productivity costs constitute the largest part of the total cost-off-illness of RA and AS reflecting the high burden of the disease on work participation. Although total and direct costs of illness in RA were higher than in AS, the average age of AS patients was 10 years lower and therefore, lifetime costs associated with AS may actually be equal or higher.

KW - Ankylosing spondylitis

KW - Cost-of-illness

KW - Costs

KW - Rheumatoid arthritis

M3 - Article

VL - 27

SP - 118

EP - 123

JO - Clinical and experimental rheumatology

JF - Clinical and experimental rheumatology

SN - 0392-856X

IS - 4, Suppl. 55

M1 - CER3653

ER -

Franke LC, Ament AJHA, van de Laar MAFJ, Boonen A, Severens JL. Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. Clinical and experimental rheumatology. 2009;27(4, Suppl. 55):0118-0123. CER3653.